Partial Beclin 1 silencing aggravates doxorubicin- and Fas-induced apoptosis in HepG2 cells

Figure 7 Expression of the Bcl-X_L protein after siRNA transfection, and treatment with an agonistic anti-Fas antibody or doxorubicin (Dox). A: Representative Western blot of Bcl-X_L and β-actin; B: Quantification of the Bcl-X_L/β-actin ratio (mean ± SE for 5 experiments); C: Representative Western blot of Bcl-X_L and β-actin after incubation with or without Dox or an anti-Fas; D: Quantification of the Fas Ab- or Dox-induced change in Bcl-X_L expression (means ± SE for 4 to 5 experiments).